20 4-13grading & staging tumour markers
DESCRIPTION
KMU (IPM&R) pathologyTRANSCRIPT
![Page 1: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/1.jpg)
GRADING & STAGING TUMOUR MARKERS
kj
![Page 2: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/2.jpg)
• Prognosis of the course of the disease
• Determination of efficacy of various forms of cancer treatment require a high degree of similarity among the tumors being considered.
![Page 3: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/3.jpg)
• Systems in semiquantitative terms,
• The level of differentiation, or grade• Extent of spread of a cancer within the patient,
or stage,
![Page 4: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/4.jpg)
Grading of a cancer is based
• Degree of differentiation of the tumor cells and the number of mitoses within the tumor as presumed correlates of the neoplasm's aggressiveness.
![Page 5: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/5.jpg)
• Grades I to IV with increasing anaplasia.
• Criteria for the individual grades vary with each form of neoplasia,
• To judge the extent to which the tumor cells resemble or fail to resemble their normal counterparts.
![Page 6: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/6.jpg)
• The correlation between histologic appearance and biologic behavior is less than perfect.
• Characterize a particular neoplasm in descriptive terms,
• Well-differentiated, mucin-secreting adenocarcinoma of the stomach, or
• Highly undifferentiated, retroperitoneal malignant tumor-probably sarcoma.
![Page 7: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/7.jpg)
Cytologic grading of squamous cell carcinoma of the lung.
A. Well-differentiated (grade 1) squamous cell carcinoma
![Page 8: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/8.jpg)
Poorly differentiated (grade 3) squamous cell carcinoma. The malignant cells are difficult to identify
as being of squamous origin.
![Page 9: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/9.jpg)
• Grading of cancers has proved of less clinical value than has staging
![Page 10: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/10.jpg)
The staging of cancers
• Based on the size of the primary lesion, • Its extent of spread to regional lymph nodes, • Presence or absence of blood-borne
metastases
![Page 11: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/11.jpg)
• Great importance in the selection of the best form of therapy
• Staging has proved to be of greater clinical value than grading
![Page 12: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/12.jpg)
• Union Internationale Contre Cancer (UICC)
• American Joint Committee (AJC) on Cancer Staging.
![Page 13: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/13.jpg)
The UICC employs a classification called the TNM system-
• T for primary tumor, • N for regional lymph node involvement • M for metastases.
![Page 14: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/14.jpg)
The TNM staging varies for each specific form of cancer, but there are general principles
• With increasing size, the primary lesion is characterized as T1 to T4.
• T0 is added to indicate an in situ lesion. .
![Page 15: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/15.jpg)
• N0 would mean no nodal involvement,
whereas N1 to N3 would denote involvement of an increasing number and range of nodes
![Page 16: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/16.jpg)
• M0 no distant metastases, • M1 or sometimes M2
![Page 17: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/17.jpg)
AJC divides all cancers into stages 0 to IV
• Incorporating within each of these stages the size of the primary lesion , presence of nodal spread & distant metastases.
![Page 18: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/18.jpg)
• Stage 0. DCIS or LCIS (5-year survival rate: 92%).
• Stage I.
Invasive carcinoma 2 cm or less in diameter (including carcinoma in situ with microinvasion) without nodal involvement (5-year survival rate: 87%).
![Page 19: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/19.jpg)
Stage II• Invasive carcinoma 5 cm or less in diameter
with up to three involved axillary nodes or
• Invasive carcinoma greater than 5 cm without nodal involvement (5-year survival rate: 75%).
![Page 20: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/20.jpg)
Stage III
• Invasive carcinoma 5 cm or less in diameter with four or more involved axillary nodes;
• Invasive carcinoma greater than 5 cm in diameter with nodal involvement;
• Invasive carcinoma with 10 or more involved axillary nodes;
• Invasive carcinoma with involvement of the ipsilateral internal mammary lymph nodes; or
• Invasive carcinoma with skin involvement (edema, ulceration, or satellite skin nodules), chest wall fixation, or clinical inflammatory carcinoma (5-year survival rate: 46%).
![Page 21: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/21.jpg)
• Stage IV. Any breast cancer with distant metastases (5-year survival rate: 13%).
![Page 22: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/22.jpg)
![Page 23: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/23.jpg)
Tumor Markers
![Page 24: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/24.jpg)
Tumor MarkersBiochemical indicators of the presence of a tumor.
• A molecule that can be detected in plasma or other body fluids
• Tumor markers cannot be primary diagnosic modalities
• Utility to support the diagnosis. • Response to therapy • Indicating relapse during the
follow-up period.
•Cell-surface antigens, •Cytoplasmic proteins, •Enzymes, •Hormones.
![Page 25: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/25.jpg)
CEA A complex glycoprotein
Elevations in many benign disorders
• Alcoholic cirrhosis, • Hepatitis, • Ulcerative colitis, • Crohn disease
•60% to 90% of colorectal, •50% to 80% of pancreatic•25% to 50% of gastric and breast carcinomas
Normally produced in embryonic tissue of the gut, pancreas, and liver
![Page 26: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/26.jpg)
Lack both specificity and the sensitivity required for the detection of early cancers
• Preoperative CEA levels body burden of tumor.• Elevated CEA levels 6 weeks after therapy indicates
residual disease.• A rising CEA level indicates recurrence, with an
increase in tumor marker level often preceding clinically detectable disease.
• Serum CEA is also useful in monitoring the treatment of metastatic breast cancer.
![Page 27: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/27.jpg)
AFP Glycoprotein
• Useful indicator of hepatocellular carcinomas and germ cell tumors of the testis.
• Decline rapidly after surgical resection of liver cell cancer or treatment of germ cell tumors.
• Less regularly in carcinomas of the colon, lung, and pancreas
Early in Fetal Life,Yolk Sac, Fetal Liver & Fetal Git
Adults with cancer arising principally inLiver Germ cells of the testis.
![Page 28: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/28.jpg)
Markers Associated CancersHormonesHuman chorionic gonadotropin
Trophoblastic tumors, nonseminomatous testicular tumors
Calcitonin Medullary carcinoma of thyroid
Catecholamine PheochromocytomaEctopic hormones Paraneoplastic Syndromes
![Page 29: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/29.jpg)
Oncofetal Antigensα-Fetoprotein Liver cell cancer,
nonseminomatous germ cell tumors of testis
Carcinoembryonic antigen
Carcinomas of the colon, pancreas, lung, stomach,
IsoenzymesProstatic acid phosphatase
Prostate cancer
Neuron-specific enolase Small cell cancer of lung, neuroblastoma
![Page 30: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/30.jpg)
Specific ProteinsImmunoglobulins Multiple myeloma and other
gammopathiesProstate-specific antigen and prostate-specific membrane antigen
Prostate cancer
Mucins and Other GlycoproteinsCA-125 Ovarian cancerCA-19-9 Colon cancer, pancreatic cancerCA-15-3 Breast cancer
![Page 31: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/31.jpg)
New Molecular Markersp53, APC, RAS mutations in stool and serum
Colon cancer
p53 and RAS mutations in stool and serum
Pancreatic cancer
p53 and RAS mutations in sputum and serum
Lung cancer
p53 mutations in urine Bladder cancer
![Page 32: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/32.jpg)
Serologic Diagnosis
• Theoretically, it may be possible to diagnose cancer by detecting cancer cell products in the serum, whether these are molecules secreted by malignant cells or antigens released by periodic death of such cells.
• No general serologic screening methods exist for cancer, but several tests are of value for certain tumors
![Page 33: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/33.jpg)
Radiologic Diagnosis
• CT & (MRI) scans, are invaluable for localizing masses as part of the primary diagnosis or for staging tumors.
• As a general rule, radiologic findings suggestive of cancer must be confirmed by either cytologic or histologic examination of biopsy material before treatment can be started.
![Page 34: 20 4-13grading & staging tumour markers](https://reader035.vdocument.in/reader035/viewer/2022062319/554b48afb4c905ff268b51c6/html5/thumbnails/34.jpg)